H.C. Wainwright analyst Andrew Fein raised the firm’s price target on United Therapeutics (UTHR) to $525 from $500 and keeps a Buy rating on the shares following the Q3 report. The firm cites Tyvaso revenue growth and the “strong” early launch of Yutrepia for the target boost.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals
- United Therapeutics Reports Record Q3 2025 Results
- United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation
- Strong Growth Potential and Strategic Initiatives Drive Buy Rating for United Therapeutics